| Multiple Sclerosis, Relapsing-Remitting
Gilenya vs Mayzent
Side-by-side clinical, coverage, and cost comparison for multiple sclerosis, relapsing-remitting.Deep comparison between: Fingolimod vs Mayzent with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsMayzent has a higher rate of injection site reactions vs Fingolimod based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Mayzent but not Fingolimod, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Fingolimod
Mayzent
At A Glance
Oral
Daily
Sphingosine 1-phosphate receptor modulator
Oral
Daily
S1P receptor modulator
Indications
- Multiple Sclerosis, Relapsing-Remitting
- Clinically isolated syndrome
- Multiple Sclerosis, Secondary Progressive
- Clinically isolated syndrome
- Multiple Sclerosis, Relapsing-Remitting
- active secondary progressive multiple sclerosis
Dosing
Multiple Sclerosis, Relapsing-Remitting, Clinically isolated syndrome, Multiple Sclerosis, Secondary Progressive 0.5 mg orally once daily for adults and pediatric patients >40 kg; 0.25 mg orally once daily for pediatric patients 10 years of age and older weighing <=40 kg; may be taken with or without food; first-dose monitoring for bradycardia required.
Clinically isolated syndrome, Multiple Sclerosis, Relapsing-Remitting, active secondary progressive multiple sclerosis 2 mg orally once daily (CYP2C9 *1/*1, *1/*2, or *2/*2) or 1 mg orally once daily (CYP2C9 *1/*3 or *2/*3), each initiated with a dose titration regimen; administer tablets whole, do not split, crush, or chew.
Contraindications
- Myocardial infarction, unstable angina, stroke, TIA, decompensated heart failure requiring hospitalization, or Class III/IV heart failure within the last 6 months
- History or presence of Mobitz Type II second-degree or third-degree AV block or sick sinus syndrome without a functioning pacemaker
- Baseline QTc interval >= 500 msec
- Cardiac arrhythmias requiring anti-arrhythmic treatment with Class Ia or Class III anti-arrhythmic drugs
- Hypersensitivity to fingolimod or any excipient in fingolimod capsules
- CYP2C9 *3/*3 genotype
- Myocardial infarction, unstable angina, stroke, TIA, decompensated heart failure requiring hospitalization, or Class III or IV heart failure within the last 6 months
- Mobitz type II second-degree, third-degree AV block, or sick sinus syndrome without a functioning pacemaker
Adverse Reactions
Most common (>=10%) Headache, liver transaminase elevation, diarrhea, cough, influenza, sinusitis, back pain, abdominal pain, pain in extremity
Serious Bradyarrhythmia, AV block, infections, progressive multifocal leukoencephalopathy, macular edema, liver injury, posterior reversible encephalopathy syndrome, fetal risk, malignancies, hypersensitivity reactions
Postmarketing Hemolytic anemia, thrombocytopenia, cryptococcal infections, HPV infection, seizures including status epilepticus, melanoma, Merkel cell carcinoma, cutaneous T-cell lymphoma, Kaposi's sarcoma, squamous cell carcinoma
Most common (>=10%) headache, hypertension, transaminase increased
Serious infections, progressive multifocal leukoencephalopathy, macular edema, bradyarrhythmia and AV conduction delays, liver injury, cutaneous malignancies, posterior reversible encephalopathy syndrome, fetal risk
Postmarketing progressive multifocal leukoencephalopathy
Pharmacology
Sphingosine 1-phosphate (S1P) receptor modulator; fingolimod is metabolized to fingolimod-phosphate, which binds S1P receptors 1, 3, 4, and 5 with high affinity, blocking lymphocyte egress from lymph nodes and reducing peripheral blood lymphocyte counts, potentially reducing lymphocyte migration into the central nervous system.
Siponimod is an S1P receptor modulator that binds with high affinity to S1P receptors 1 and 5, blocking lymphocyte egress from lymph nodes and reducing peripheral blood lymphocyte counts; the therapeutic mechanism in multiple sclerosis is unknown but may involve reduction of lymphocyte migration into the central nervous system.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Fingolimod
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (2/12) · Qty limit (11/12)
Mayzent
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (1/12) · Qty limit (9/12)
UnitedHealthcare
Fingolimod
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (8/8)
Mayzent
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (0/8) · Qty limit (4/8)
Humana
Fingolimod
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (3/3)
Mayzent
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Multiple Sclerosis: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAccessia Health: Multiple Sclerosis - Private Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
FingolimodView full Fingolimod profile
MayzentView full Mayzent profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.